The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, shares the results of a study investigating the impact of cytogenetic abnormalities observed at diagnosis on the outcomes of pediatric patients with acute myeloid leukemia (AML) with poor-risk cytogenetic abnormalities following stem cell transplantation (SCT). The study reported that cytogenetic abnormalities at diagnosis are predictive of overall survival (OS) following SCT in pediatric patients. In addition, whilst monosomy 7/del7q or monosomy 5/del5q were found to confer a poor prognosis following HCT, 11q23 abnormality and other poor-risk abnormalities were associated with favorable outcomes after SCT. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Spotlight Therapeutics: Consultancy; CRISPR Therapeutics: Other: Clinical Trial Site PI, Research Funding; Novartis: Other: Clinical Trial Site PI; Magenta Therapeutics: Other: Clinical Trial Site PI; Vindico Medical Education: Honoraria; Medexus Inc: Consultancy; Vertex Pharmaceuticals/CRISPR Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Clinical Trial Site PI.
